PolyPid Ltd. Ordinary Shares (PYPD)

Price$4.66

Favorite Metrics

Price vs S&P 500 (26W)33.62%

Price vs S&P 500 (4W)1.69%

Market Capitalization$90.07M

All Metrics

Book Value / Share (Quarterly)$0.60

P/TBV (Annual)1.12x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.54

Price vs S&P 500 (YTD)6.11%

EPS (TTM)$-2.26

10-Day Avg Trading Volume0.06M

EPS Excl Extra (TTM)$-2.26

EPS (Annual)$-2.09

ROI (Annual)-285.67%

Cash / Share (Quarterly)$0.71

ROA (Last FY)-153.18%

EBITD / Share (TTM)$-1.93

ROE (5Y Avg)-307.35%

Cash Flow / Share (Annual)$-1.54

P/B Ratio8.21x

P/B Ratio (Quarterly)6.29x

Net Income / Employee (Annual)$-0

Net Interest Coverage (TTM)40.47x

ROA (TTM)-131.82%

EPS Incl Extra (Annual)$-2.09

Current Ratio (Annual)1.97x

Quick Ratio (Quarterly)1.70x

3-Month Avg Trading Volume0.07M

52-Week Price Return85.10%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.14

52-Week High$5.12

EPS Excl Extra (Annual)$-2.09

CapEx CAGR (5Y)-23.08%

26-Week Price Return37.61%

Quick Ratio (Annual)1.77x

13-Week Price Return1.51%

Total Debt / Equity (Annual)0.09x

Current Ratio (Quarterly)1.97x

Enterprise Value$84.659

Revenue / Employee (Annual)$0

Cash / Share (Annual)$0.71

3-Month Return Std Dev46.33%

Net Income / Employee (TTM)$-0

ROE (Last FY)-311.39%

Net Interest Coverage (Annual)-20.86x

EPS Basic Excl Extra (Annual)$-2.09

Total Debt / Equity (Quarterly)0.09x

EPS Incl Extra (TTM)$-2.26

ROI (TTM)-214.46%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$8.81

Price vs S&P 500 (52W)55.27%

Year-to-Date Return8.76%

5-Day Price Return8.01%

EPS Normalized (Annual)$-2.09

ROA (5Y Avg)-134.43%

Month-to-Date Return7.76%

EBITD / Share (Annual)$-2.01

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-174.78%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.26

P/TBV (Quarterly)1.85x

P/B Ratio (Annual)6.29x

Book Value / Share (Annual)$0.60

Price vs S&P 500 (13W)0.82%

Beta1.51x

Revenue / Share (TTM)$0.00

ROE (TTM)-291.42%

52-Week Low$2.44

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.10

About

PolyPid Ltd is a clinical-stage biopharmaceutical company developing therapies based on PLEX, its proprietary drug delivery technology that enables targeted, localized drug release over extended periods. The company's lead candidate, D-PLEX100, is being developed to prevent surgical site infections, while OncoPLEX represents a potential intra-tumoral cancer treatment platform.